plagiochin E: reverses multidrug resistance; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 16757518 |
| CHEMBL ID | 1956724 |
| MeSH ID | M0522794 |
| Synonym |
|---|
| CHEMBL1956724 |
| plagiochin e |
| 2-oxapentacyclo[22.2.2.13,7.010,15.016,21]nonacosa-1(26),3,5,7(29),10(15),11,13,16(21),17,19,24,27-dodecaene-4,12,17-triol |
Plagiochin E is an antifungal active macrocyclic bis(bibenzyl) isolated from liverwort Marchantia polymorpha L.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Plagiochin E (PLE) is an antifungal macrocyclic bis(bibenzyl) isolated from liverwort Marchantia polymorpha L. " | ( Plagiochin E, an antifungal bis(bibenzyl), exerts its antifungal activity through mitochondrial dysfunction-induced reactive oxygen species accumulation in Candida albicans. Cheng, AX; Lou, HX; Sun, LM; Sun, SJ; Wu, XZ, 2009) | 3.24 |
| "Plagiochin E (PLE) is an antifungal active macrocyclic bis(bibenzyl) isolated from liverwort Marchantia polymorpha L. " | ( Plagiochin E, an antifungal active macrocyclic bis(bibenzyl), induced apoptosis in Candida albicans through a metacaspase-dependent apoptotic pathway. Chang, WQ; Cheng, AX; Lou, HX; Sun, LM; Wu, XZ, 2010) | 3.25 |
| "Plagiochin E is a new macrocyclic bisbibenzyl compound isolated from Marchantia polymorpha. " | ( Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells. Cheng, YN; Li, S; Liao, YX; Lou, HX; Qu, XJ; Shi, YQ; Xie, CF, 2008) | 2.05 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In order to understand the underlying mechanisms, we studied the effects of PLE alone and in combination with fluconazole (FLC) on the ergosterol biosynthetic pathway against both FLC-sensitive and FLC-resistant strains by analyzing the sterol content and the ergosterol pathway gene (ERG) expression." | ( The effect of plagiochin E alone and in combination with fluconazole on the ergosterol biosynthesis of Candida albicans. Cheng, AX; Lou, HX; Lv, BB; Sun, LM; Wu, XZ, 2009) | 0.71 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID650266 | Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7 | Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents. |
| AID650265 | Growth inhibition of human MCF7 cells at 20 uM after 24 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7 | Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents. |
| AID650274 | Cytotoxicity against human PC3 cells after 24 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7 | Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents. |
| AID650264 | Growth inhibition of human PC3 cells at 20 uM after 24 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7 | Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents. |
| AID650267 | Cytotoxicity against human KB cells after 24 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7 | Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents. |
| AID650275 | Growth inhibition of human KB cells at 20 uM after 24 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7 | Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||